bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2025.10.24.684257

Uncovering novel therapeutics for schizophrenia: a multitarget approach using the CANDO platform

Hu, Y.·Samudrala, R.·Falls, Z.
View original source ↗Export metadata ↓

Abstract

Schizophrenia is a complex and debilitating neuropsychiatric disorder characterized by positive, negative, and cognitive symptoms, many remaining insufficiently addressed by current treatments. High rates of treatment resistance and heterogeneous pathophysiology pose significant challenges to traditional single-target drug discovery. To address this, we applied the CANDO platform to identify repurposable drugs for schizophrenia using a multitarget strategy. The platform evaluates how compounds interact with the entire human proteome, generating interaction signatures that capture a compounds effect across all targets. By comparing these signatures, CANDO computes compound similarity scores and enables consensus prediction of novel therapeutics. Across all indications and for schizophrenia in particular, CANDO outperformed controls by orders of magnitude across several benchmarking metrics, accurately recovering known drug-indication relationships. We applied our CANDO pipeline, benchmarked by its ability to recover approved drugs for their indications using similarity- and consensus-based metrics, to generate a ranked list of repurposable compounds. Our comprehensive literature review confirmed clinical or biochemical evidence supporting 25 high-corroboration drug candidates, including phenothiazine and benzamide antipsychotics, tricyclic antidepressants, benzodiazepines, and monoamine oxidase inhibitors. We identified protein targets with the highest likelihood of interaction with these top drugs and assessed prediction quality through overlap analysis with gold standards, showing significantly better concordance with established schizophrenia-related biology than controls from bottom-ranked and randomly selected drugs. Among these proteins are corroborated targets such as canonical neurotransmitter receptors of the dopamine, serotonin, and adrenergic classes, as well as monoamine transporters, tyrosine aminotransferase, and lysine-specific histone demethylase 1A. Enrichment of calcium-binding proteins among the top predicted targets for the phenothiazine antipsychotic thiethylperazine highlights a potential role for dysregulated calcium signaling, including calmodulin-CaMKK2 pathways, in schizophrenia pathology and treatment response. Another phenothiazine antipsychotic, triflupromazine, binds the serotonin transporter in addition to its canonical dopamine D2 receptor interaction, highlighting its potential relevance to depressive symptom modulation in schizophrenia. These findings demonstrate the utility and accuracy of the CANDO platform in elucidating multitarget pharmacological mechanisms and accelerating the identification of effective repurposable treatments for schizophrenia.

Explore related subjects

bioinformaticsPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Hu, Y., Samudrala, R., Falls, Z.. 2025-10-26. Uncovering novel therapeutics for schizophrenia: a multitarget approach using the CANDO platform. https://doi.org/10.1101/2025.10.24.684257

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Cross-modal transfer enables zero-shot prediction of drug responses across cell types

Genetic perturbation responses capture the functional consequences of gene-level interventions, providing functional information for drug-response prediction beyond baseline gene expression. Within the same cellular context, genetic and chemical perturbations engage shared regulatory networks, providing a biological basis for transferring response information between perturbation modalities. Here we introduce GRAFT, a framework that combines genetic-to-chemical transfer with cross-context prediction to infer drug-induced transcriptional responses without drug measurements in the target context. Across benchmarked LINCS and external contexts, GRAFT improved response correlation, directional agreement and magnitude reconstruction over competing methods, particularly for drugs with context-dependent responses. GRAFT-Adapt further refines predictions of unmeasured responses using a small number of drug measurements from the target context. GRAFT-Atlas spans 13 cellular contexts and 7,856 drug catalog entries, comprising 102,128 predictions for drug-context combinations. The atlas captured recognizable pharmacological neighborhoods, shared functional programs, context-dependent transcriptional changes and structural-functional associations supported by molecular docking. Across ten iPSC lines from distinct donors, GRAFT identified candidate inter-donor differences, with functional support for selected candidates from measured genetic perturbation responses. Together, GRAFT enables perturbation-informed prediction and comparison of drug responses across cellular contexts.

bioinformatics↗
bioRxiv2026

Pycea: a scverse toolkit for single-cell lineage tracing analysis

Lineage tracing enables reconstruction of cellular histories in development, regeneration, and disease, but integrating lineage data into single-cell analysis workflows remains challenging. We introduce Pycea, a Python toolkit for lineage analysis and visualization, and TreeData, an extension of AnnData that stores lineage trees alongside cellular measurements. TreeData is compatible with Scanpy and other scverse tools, enabling integrated analysis without converting between formats. Pycea provides scalable methods for tree visualization, clade identification, distance comparisons, ancestral state inference, and lineage statistics. This software is open source and available at https://github.com/YosefLab/pycea.

bioinformatics↗
bioRxiv2026

Transcript quantification using context-aware MAPQ modeling

Long-read RNA-sequencing enables accurate transcript-level quantification, but prior static filtering of MAPping Quality (MAPQ) can ignore transcriptome-intrinsic ambiguity, and discarding reads on this basis distorts abundance estimates. We present CALMeR (Context-Aware Long-read MAPQ-based Rescuer), which conditions MAPQ filtering on transcript properties rather than a fixed cutoff. CALMeR fits a zero-one inflated beta regression on various transcript and read-level features to model the expected MAPQ distribution for each alignment. Reads whose MAPQ fits this context, such as low-MAPQ reads from multi-isoform genes and paralog families are retained; reads with anomalously low MAPQ are removed as likely artifacts. Retained reads can be summed per transcript or passed to any downstream quantifier. Compared with a MAPQ [≥] 1 filter and expectation-maximization-based transcript quantification methods, CALMeR recovers more spike-in transcripts and better matches known spike-in concentrations. CALMeR is available at https://github.com/sparthib/CALMeR.

bioinformatics↗